COMMENTARY

What if Google or Amazon Designed Clinical Trials?

Were High-Risk Patients the Wrong Targets in CASSINI and AVERT?

F. Perry Wilson, MD, MSCE

Disclosures

February 27, 2019

Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I'm Perry Wilson.

This week: Two studies, both alike in dignity, in the New England Journal of Medicine, where we lay our scene. Yes, we're going to examine the CASSINI and AVERT trials, both of which evaluated whether oral anticoagulants would prevent venous thrombosis in high-risk patients with cancer.[1,2] And I'm excited to talk about these studies because they lay bare a central intuition of clinical trial design that I don't think is necessarily true.

Let's start at the beginning. Individuals with cancer are at risk of developing blood clots, but prevention requires the use of blood-thinning medications, which themselves carry substantial risk. Physicians and patients are not always great at balancing risks and benefits, so it would really help if we had strong data to guide us.

We had a bit. Prior to the recent publications, two large randomized trials[3,4] had examined the use of low-molecular-weight heparin (LMWH) in ambulatory patients with cancer and found a significant reduction in the risk for clot, from about 4% to 2%—meaning, you'd have to treat 50 people with LMWH to prevent one clot.


 

For a high-risk drug, that felt like a lot. To prevent one clot, we're essentially treating 49 people unnecessarily. Moreover, neither study showed a difference in overall mortality. So practice wasn't really changed.

Enter a bit of intuition that I will argue is wrong. It goes like this: Imagine a population of individuals, all of whom have a different baseline risk of developing a blood clot. Instead of enrolling this diverse group in your trial, select just those at highest risk.


 

This is a process called "enrichment." The idea is that, if a drug is moderately efficacious among a given population, it will be more efficacious among members of the population at highest risk. Sounds good, right? Also, through enrichment, you increase the outcome rate in your trial, meaning, you have to enroll fewer people and therefore spend less money—assuming, of course, that the drug works just as well in high-risk individuals as it does in other risk groups.

But that assumption, though intuitive, is not necessarily true. It assumes that the relative risk of outcome among the treated group is the same across risk categories. To do the math, let's imagine that a drug reduces the rate of thrombosis by 50%.


 

Well, we could take a low-risk group and reduce their rate of thrombosis from 1% to 0.5% (a number needed to treat of 200), or a high-risk group and reduce their rate of thrombosis from 20% to 10% (a number needed to treat of 10). Which would you choose?

But why should a drug have the same relative effect in people at high risk and low risk?

Maybe people at very high risk are so high-risk that the drug will have no effect; I call this the "blowing against the wind" phenomenon.


 

Nevertheless, it was the hope of the CASSINI and AVERT trials to target individuals with a high risk for blood clot based on the validated Khorana score, which takes into account the type of cancer and a variety of lab parameters, in order that the overall effect would be compelling enough to lead us to a new standard of care.

Source: Khorana AA, et al[5]

So, what did they find? Nothing to settle the debate, I'm afraid. CASSINI randomized 841 patients to rivaroxaban (Xarelto) 10 mg daily.

Source: Khorana AA, et al,[1] Carrier M, et al[2]

The rate of blood clot was 8.8% in the placebo group and 6% in the intervention group, a nonsignificant reduction with a number needed to treat of 36. AVERT randomized 563 patients to apixaban (Eliquis) 2.5 mg twice daily. The rate of blood clot was 10.2% in the placebo group and 4.2% in the intervention group, a number needed to treat of 17.

It may seem that apixaban won this contest, but remember that these are two separate trials, not a head-to-head comparison.

But don't go rushing to the prescription pad yet. The overall death rate was 12.2% in the apixaban group compared with 9.8% in the control group.

Source: Carrier M, et al[2]

That's right: fewer clots, more deaths. Not great.

Why weren't these trials slam dunks? Because that intuition—that drugs always work better in sicker people—is not correct. In fact, cancer is a particularly good example. The individuals at highest risk of blood clots are the very ones at highest risk of dying from their cancer, and preventing a blood clot may do little to avoid that outcome.

Is there a fix for this?

Actually, there is, and it's been staring us in the face for a while. Facebook, Amazon, and Google have been doing it for a decade to more efficiently target ads to consumers. It's called "uplift" or "individual treatment effect" modeling, and the idea is to enroll patients not based on their risk for a given outcome but on their chance of responding to therapy. These models allow for the fact that, sometimes, a particular therapy might work best in those at moderate risk, or even at low risk. If you're interested, I've written about this elsewhere.[6]

Until we move to a smarter type of clinical trial enrichment, we're going to remain frustrated at how hard it is to figure out just who is a good candidate for a risky therapy. Those at highest risk, counterintuitively, may be exactly the wrong ones to target.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....